Gilead Sciences Inc. (GILD)
GILD trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$147.92
-1.67% on the day
Market cap
$183.4B
Large cap
Revenue · 2025
$29.4B
+2.4% on 2024
Net income · 2025
$8.5B
28.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | GILD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 1992 |
| SEC CIK | 0000882095 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $29.4B |
| Net income | $8.5B |
| Operating income | $10.0B |
| Net margin | 28.9% |
| Operating margin | 34.0% |
| Revenue growth | +2.4% |
| Cash | Not in SEC XBRL data |
| Total assets | $59.0B |
| P/E (computed) | 21.6× |
| P/S (computed) | 6.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-08-06 |
| Latest annual report FORM 10-K | 10-K | 2026-02-24 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-06 |
| Latest current report FORM 8-K | 8-K | 2026-08-04 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-03-20 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.6% |
| 1 month | +4.9% |
| 3 months | +12.6% |
| Year to date | +25.1% |
| 1 year | +29.9% |
| From 52-week high | -1.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AMGN | Amgen Inc. | $412.84 | -1.13% | $223.2B |
| MRNA | Moderna Inc. | $216.25 | +1.17% | $86.3B |
| ARGX | argenx SE | $802.64 | -1.19% | $49.8B |
| RVMD | Revolution Medicines Inc. | $188.44 | -2.84% | $40.4B |
| BIIB | Biogen Inc. | $228.90 | -0.22% | $33.8B |
| BNTX | BioNTech SE American Depositary Share | $89.01 | -7.13% | $22.4B |
| EXEL | Exelixis Inc. | $59.51 | -0.52% | $14.7B |
| NBIX | Neurocrine Biosciences Inc. | $135.13 | -4.41% | $13.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier